All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked: Do you see improved outcomes when adding magrolimab to azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment?
In this video, Naval Daver describes patient characteristics, the safety and efficacy results from an ongoing trial. He also explains the rationale behind focusing on patients with TP53 mutations and describes the encouraging survival rates, duration of response and remission.
Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?
Your opinion matters
Naval Daver | EHA 2018 | Immune-based therapy in AML
Naval Daver: MD Anderson Cancer Center, Houston, US Interview topic: Immune-based therapy in AML
Magrolimab plus azacytidine in patients with myelodysplastic syndromes and acute myeloid leukemia
During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the Moffitt Cancer Center, US, presented an abstract...
Subscribe to get the best content related to AML delivered to your inbox